-
NantHealth has validated successful DeviceConX™ integration with
Baxter’s Prismaflex system, used to treat critically-ill
patients in the ICU
-
Connectivity is being used in multiple U.S. hospitals
-
Baxter and NantHealth are also working on Baxter’s next generation
medical devices and expect DeviceConX™ validation at launch
ORLANDO, Fla.--(BUSINESS WIRE)--
NantHealth (NASDAQ: NH), a leader in connected care solutions, and
Baxter International Inc. (NYSE:BAX), a global medical products company,
today announced that a NantHealth digital health solution is now
available to connect Baxter’s Prismaflex system to a hospital
electronic medical record (EMR). Prismaflex is used in the
intensive care unit (ICU) to treat patients with acute kidney injury
(AKI) and certain blood and autoimmune conditions, which can be
life-threatening. The companies are demonstrating the technology at the
2019 Healthcare Information and Management Systems Society (HIMSS)
Interoperability Showcase™ this week.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190211005225/en/
The Prismaflex system is used in the intensive care unit (ICU) to treat patients with acute kidney injury (AKI) and certain blood and autoimmune conditions, which can be life-threatening. (Photo: Business Wire)
ICU clinicians treat patients with the most serious and complex
conditions. Care in the ICU is also multi-disciplinary, with several
specialists and nurses providing care for these complex cases. Despite
these factors, technology and medical devices in the ICU remain largely
disconnected and fragmented. These dynamics mean digital health
solutions have the potential to positively impact patient care and
hospital efficiency.
NantHealth has built a device driver allowing integration of its
DeviceConX platform with the Prismaflex system. NantHealth’s
DeviceConX works with various electronic medical record (EMR) systems
and enables straightforward integration of information from the device
to the EMR. This means ICU nurses can spend less time manually
documenting treatment data, while reducing the risk of transcription
errors. NantHealth and Baxter are also working to validate drivers for
Baxter’s next generation medical devices designed for the ICU.
“The ICU requires coordinated care among specialists and nurses, further
complicated by the need to manage data streams from numerous medical
devices,” said Brian Tufts, Baxter’s lead for Acute Therapies in the
U.S. “When customers use technology to streamline connectivity of Prismaflex
to their IT systems, busy nurses are no longer tasked with manually
charting treatment data. We are excited about this development as we
work to create digital health solutions to help our customers turn data
into meaningful insights to improve patient care.”
“Connected care solutions like those created by NantHealth provide
important information for care team members to make more informed
decisions about their patients,” said Wesley Madden, BSN, RN, vice
president of Connected Care for NantHealth. “We’re proud to work with
innovative companies like Baxter, who understand the importance of
giving clinicians the very best tools and data to deliver the highest
quality care possible.”
NantHealth will be showcasing Baxter’s recently integrated Prismaflex
device in the HIMSS Interoperability Showcase in Hall F - Booth #9100,
which brings together multiple vendors with kidney and dialysis
treatment solutions.
Prismaflex is Rx Only: For safe and proper use of the devices
mentioned herein, refer to the complete instructions in the Operator's
Manual. The Prismaflex system is intended for continuous renal
replacement therapies (CVVHDF, CVVHD, CVVH, SCUF) and therapeutic plasma
exchange (TPE). The Prismaflex system should be restricted to
patients with a body weight greater than 20 kg (44 lb).
About Acute Kidney Injury
Acute kidney injury (AKI) is a sudden decrease in kidney function over a
period of hours to days, often the result of illness, trauma or
infection. The sudden loss of kidney function leads to the accumulation
of toxins and fluid in the blood that, if left untreated, may lead to
death. The most severe stage of AKI requires renal replacement therapy
to replace the function of healthy kidneys. AKI is an increasingly
common complication of acute illnesses in intensive care units and
hospitals.1,2,3
About NantHealth
NantHealth provides innovative solutions across the continuum of care
for patients, physicians, payers and biopharmaceutical organizations.
Connected Care, NantHealth’s Medical Device Interoperability (MDI)
solution, provides hundreds of healthcare facilities across the globe
with vendor-neutral device connectivity. Our combined hardware-software
offering delivers high resolution, low-latency medical device data to a
broad range of clinical systems, including EMRs and research databases.
For more information, please visit https://www.nanthealth.com/.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we’ve been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter’s employees
worldwide are now building upon the company’s rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit baxter.com
and follow us on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning the EMR
technology and Prismaflex system referred to in this release,
including anticipated benefits associated with their use and anticipated
production certifications, and a potential partnership between Baxter
and NantHealth. The statements are based on assumptions about many
important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking
statements: satisfaction of regulatory and other requirements; actions
of regulatory bodies and other governmental authorities; product
quality, manufacturing or supply issues; patient safety issues; changes
in law and regulations; breaches or failures of the company’s
information technology systems or products, including by cyberattack,
unauthorized access or theft; and other risks identified in Baxter's
most recent filing on Form 10-K and other SEC filings, all of which are
available on Baxter's website. Baxter does not undertake to update its
forward-looking statements.
Baxter and Prismaflex are registered trademarks of Baxter
International Inc.
1 Siew ED, Davenport A: The growth of acute kidney injury: a
rising tide or just closer attention to detail? Kidney Int 2015;87:46-61.
2 O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and
associations of acute kidney injury after major abdominal surgery.
Intensive Care Med 2016;42:521-530.
3 Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani
F, Koulouridis I, Jaber BL: World incidence of AKI: a meta-analysis.
Clin J Am Soc Nephrol 2013;8:1482-1493.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190211005225/en/
Baxter Media Contact
Lauren Russ, (224) 948-5353
media@baxter.com
NantHealth Media Contact
Jen Hodson, (562) 397-3639
jen@nantworks.com
Baxter Investor Contact
Clare Trachtman, (224) 948-3085
Source: Baxter International Inc.